RENAGADE Trademark

Trademark Overview

On Saturday, February 20, 2021, a trademark application was filed for RENAGADE with the United States Patent and Trademark Office. The USPTO has given the RENAGADE trademark a serial number of 90537289. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Friday, August 30, 2024. This trademark is owned by Renagade Therapeutics LLC. The RENAGADE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; medical and scientific research in the field of cancer treatment and diagnosis; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines, namely, RNA and DNA vaccines; research and development services in the field of antibodies; scientific research for medical purposes in the area of cancerous diseases; scientific research for medical purposes in the field of nucleic acids, namely, RNA and DNA therapeutics for use in the treatment of rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, muscular disorders, reproductive disorders, infectious diseases, blood disorders, sepsis, alopecia, and cognitive disorders; scientific resear...
renagade

General Information

Serial Number90537289
Word MarkRENAGADE
Filing DateSaturday, February 20, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateFriday, August 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 17, 2023

Trademark Statements

Pseudo MarkRENEGADE
Goods and ServicesDesign, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; medical and scientific research in the field of cancer treatment and diagnosis; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines, namely, RNA and DNA vaccines; research and development services in the field of antibodies; scientific research for medical purposes in the area of cancerous diseases; scientific research for medical purposes in the field of nucleic acids, namely, RNA and DNA therapeutics for use in the treatment of rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, muscular disorders, reproductive disorders, infectious diseases, blood disorders, sepsis, alopecia, and cognitive disorders; scientific research in the field of inhibitory nucleic acids, protein-encoding nucleic acids and polypeptide-encoding nucleic acids; pharmaceutical research and development; product research and development; scientific research and development; vaccine research and development in the field of RNA and DNA vaccines

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, May 21, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameRenagade Therapeutics LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142
Party NameRenagade Therapeutics LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Wednesday, February 24, 2021NEW APPLICATION ENTERED
Friday, May 21, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 15, 2021ASSIGNED TO EXAMINER
Wednesday, September 15, 2021NON-FINAL ACTION WRITTEN
Wednesday, September 15, 2021NON-FINAL ACTION E-MAILED
Wednesday, September 15, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, March 29, 2022TEAS PETITION TO REVIVE RECEIVED
Tuesday, March 29, 2022PETITION TO REVIVE-GRANTED
Tuesday, March 29, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 29, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, March 29, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Wednesday, March 30, 2022NOTICE OF REVIVAL - E-MAILED
Thursday, March 31, 2022ASSIGNED TO LIE
Friday, April 1, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, April 1, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 4, 2022FINAL REFUSAL WRITTEN
Wednesday, May 4, 2022FINAL REFUSAL E-MAILED
Wednesday, May 4, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, October 13, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, October 13, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 13, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 13, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 13, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, November 4, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, November 4, 2022EXPARTE APPEAL RECEIVED AT TTAB
Friday, November 4, 2022JURISDICTION RESTORED TO EXAMINING ATTORNEY
Friday, November 4, 2022EX PARTE APPEAL-INSTITUTED
Monday, November 7, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 7, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 14, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 28, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, December 30, 2022EXPARTE APPEAL TERMINATED
Tuesday, January 17, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 17, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 14, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 12, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, September 12, 2023SOU EXTENSION 1 FILED
Tuesday, September 12, 2023SOU EXTENSION 1 GRANTED
Thursday, September 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 21, 2024SOU EXTENSION 2 FILED
Wednesday, February 21, 2024SOU EXTENSION 2 GRANTED
Wednesday, February 21, 2024SOU TEAS EXTENSION RECEIVED
Thursday, February 22, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 30, 2024SOU TEAS EXTENSION RECEIVED
Friday, August 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 30, 2024SOU EXTENSION 3 GRANTED
Friday, August 30, 2024SOU EXTENSION 3 FILED

Related Keywords

renagade disorders research scientific medical development field diseases purposes treatment vaccines